These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28412959)

  • 1. Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery.
    Chen B; Altman RB
    Orphanet J Rare Dis; 2017 Apr; 12(1):61. PubMed ID: 28412959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing drugs for rare genetic diseases: trends and insights.
    Zitter M
    Manag Care; 2005 Feb; 14(2):52-4, 57-60, 63-4; quiz 66-7. PubMed ID: 15782848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finding chemical drugs for genetic diseases.
    Sun HY; Hou TJ; Zhang HY
    Drug Discov Today; 2014 Dec; 19(12):1836-40. PubMed ID: 25256778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in orphan drug development and regulatory policy in China.
    Cheng A; Xie Z
    Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A generalizable pre-clinical research approach for orphan disease therapy.
    Beaulieu CL; Samuels ME; Ekins S; McMaster CR; Edwards AM; Krainer AR; Hicks GG; Frey BJ; Boycott KM; Mackenzie AE
    Orphanet J Rare Dis; 2012 Jun; 7():39. PubMed ID: 22704758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
    Lutz T; Lampert A; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery and development for rare genetic disorders.
    Sun W; Zheng W; Simeonov A
    Am J Med Genet A; 2017 Sep; 173(9):2307-2322. PubMed ID: 28731526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orphan drug development: Challenges, regulation, and success stories.
    Chirmule N; Feng H; Cyril E; Ghalsasi VV; Choudhury MC
    J Biosci; 2024; 49():. PubMed ID: 38383975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare genetic diseases: update on diagnosis, treatment and online resources.
    Pogue RE; Cavalcanti DP; Shanker S; Andrade RV; Aguiar LR; de Carvalho JL; Costa FF
    Drug Discov Today; 2018 Jan; 23(1):187-195. PubMed ID: 29129805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repositioning for orphan diseases.
    Sardana D; Zhu C; Zhang M; Gudivada RC; Yang L; Jegga AG
    Brief Bioinform; 2011 Jul; 12(4):346-56. PubMed ID: 21504985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal therapy for rare disorders and genetic diseases: ethical and political challenges.
    MacLeod S
    Proc West Pharmacol Soc; 2007; 50():21-3. PubMed ID: 18605224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The unsolved rare genetic disease atlas? An analysis of the unexplained phenotypic descriptions in OMIM®.
    Hartley T; Balcı TB; Rojas SK; Eaton A; Canada CR; Dyment DA; Boycott KM
    Am J Med Genet C Semin Med Genet; 2018 Dec; 178(4):458-463. PubMed ID: 30580481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Modifiers and Rare Mendelian Disease.
    Rahit KMTH; Tarailo-Graovac M
    Genes (Basel); 2020 Feb; 11(3):. PubMed ID: 32106447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.